Analyst firms · H.C. Wainwright · DCPH
H.C. Wainwright DCPH price target and rating history
Deciphera Pharmaceuticals Inc. (DCPH) · Health Care
H.C. Wainwright rates Deciphera Pharmaceuticals Inc. (DCPH) Buy with a $15 price target, as of its latest action on Dec 1, 2021. It has published 3 rating actions on DCPH since August 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Buy
- Price target
- $15
- Median target, all firms
- Too few
- Actions on DCPH
- 3
H.C. Wainwright price target on DCPH
Every H.C. Wainwright rating on DCPH
- Dec 1, 2021
- Nov 8, 2021
- Aug 4, 2021
Questions about H.C. Wainwright and DCPH
- What is H.C. Wainwright's price target for DCPH?
- H.C. Wainwright's latest stated price target for Deciphera Pharmaceuticals Inc. (DCPH) is $15, from its action on Dec 1, 2021.
- What is H.C. Wainwright's rating on DCPH?
- H.C. Wainwright rates DCPH Buy, a bullish rating, as of Dec 1, 2021.
- When did H.C. Wainwright last change its view on DCPH?
- On Dec 1, 2021, H.C. Wainwright cuts its price target to $15 from $25, keeps Buy.
More DCPH rating histories
All H.C. Wainwright ratingsDCPH news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.